Nitric oxide inhalation and glucocorticoids as combined treatment in human experimental endotoxemia

Critical Care Medicine

Volumn 36, Issue 11, 2008, Pages 3043-3047

  Hållsträm, Lars ^a   Berghäll, Elisabeth ^a   Frostell, Claes ^a   Sollevi, Alf ^a   Soop, Anne L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytokines; Inflammation; Nitric oxide; Receptor for advanced glycation end products; Sepsis; Volunteers

Indexed keywords

ENDOTOXIN; HYDROCORTISONE SODIUM SUCCINATE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; NITRIC OXIDE; NITROGEN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; DRUG DERIVATIVE; GLUCOCORTICOID; HYDROCORTISONE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; BODY TEMPERATURE; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOKINE RELEASE; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; EXPERIMENTAL MODEL; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; INTENSIVE CARE UNIT; LOW DRUG DOSE; MALE; NASOGASTRIC TUBE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNIVERSITY HOSPITAL; ADULT; BLOOD; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ADMINISTRATION, INHALATION; ADULT; BODY TEMPERATURE; CROSS-OVER STUDIES; CYTOKINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTOXEMIA; FEMALE; GLUCOCORTICOIDS; HEART RATE; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; NITRIC OXIDE;

EID: 56049120313     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318186f5b2     Document Type: Article

References (40)

1. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 2005; 365:63-78
2. Cronstein BN: Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994; 76:5-13
3. Murphy K, Haudek SB, Thompson M, et al: Molecular biology of septic shock. New Horiz 1998; 6:181-193
4. Lowenthal JW, Ballard DW, Bohnlein E, et al: Tumor necrosis factor alpha induces proteins that bind specifically to kappa B-like enhancer elements and regulate interleukin 2 receptor alpha-chain gene expression in primary human T lymphocytes. Proc Natl Acad Sci USA 1989; 86:2331-2335
5. Kokkola R, Andersson A, Mullins G, et al: RAGE is the major receptor for the proin-flammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 1-9
6. Lalla E, Lamster IB, Stern DM, et al: Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: Mechanisms and insights into therapeutic modalities. Ann Periodontol 2001; 6:113-118
7. Pullerits R, Bokarewa M, Dahlberg L, et al: Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005; 7:R817-R824
8. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-1978
9. Radomski MW, Palmer RM, Moncada S: Glucocorticoids inhibit the expression of an in- ducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990; 87:10043-10047
10. Ignarro LJ, Buga GM, Wood KS, et al: Endo-thelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269
11. Chollet-Martin S, Gatecel C, Kermarrec N, et al: Alveolar neutrophil functions and cyto-kine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation. Am J Respir Crit Care Med 1996; 153:985-990
12. Takenaka K, Nishimura Y, Nishiuma T, et al: Ventilator-induced lung injury is reduced in transgenic mice that overexpress endothelial nitric oxide synthase. Am J Physiol Lung Cell Mol Physiol 2006; 290:L1078-L1086
13. Thomassen MJ, Buhrow LT, Connors MJ, et al: Nitric oxide inhibits inflammatory cyto-kine production by human alveolar macro-phages. Am J Respir Cell Mol Biol 1997; 17:279-283
14. Griffiths MJ, Evans TW: Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353: 2683-2695
15. Taylor RW, Zimmerman JL, Dellinger RP, et al: Low-dose inhaled nitric oxide in patients with acute lung injury: A randomized controlled trial. JAMA 2004; 291:1603-1609
16. Raychaudhuri B, Dweik R, Connors MJ, et al: Nitric oxide blocks nuclear factor-kappaB activation in alveolar macrophages. Am J Respir Cell Mol Biol 1999; 21:311-316
17. Kang JL, Park W, Pack IS, et al: Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation. J Appl Physiol 2002; 92: 795-801
18. Adcock IM, Caramori G: Cross-talk between pro-inflammatory transcription factors and glucocorticoids. Immunol Cell Biol 2001; 79: 376-384
19. Kagoshima M, Ito K, Cosio B, et al: Glucocorticoid suppression of nuclear factor-kappa B: A role for histone modifications. Biochem Soc Trans 2003; 31(Pt 1):60-65
20. Luce JM, Montgomery AB, Marks JD, et al: Ineffectiveness of high-dose methylpred-nisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138:62-68
21. Bone RC, Fisher CJ Jr, Clemmer TP, et al: A controlled clinical trial of high-dose methyl-prednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-658
22. Bollaert PE, Charpentier C, Levy B, et al: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-650
23. Carlet J: From mega to more reasonable doses of corticosteroids: A decade to recreate hope. Crit Care Med 1999; 27:672-674
24. Santos AA, Scheltinga MR, Lynch E, et al: Elaboration of interleukin 1-receptor antag- onist is not attenuated by glucocorticoids after endotoxemia. Arch Surg 1993; 128: 138-143; discussion 143-134
25. Almqvist PM, Ekstrom B, Kuenzig M, et al: Effect of high dose corticosteroids alone or combined with other drugs on survival in septic shock. Acta Chir Scand Suppl 1985; 526:120-123
26. Hedenstierna G, Da JP, Chen L: Upregulation of the glucocorticoid receptor by inhaled nitric oxide and enhanced anti-inflammatory effects by steroids in a porcine sepsis model [abstract]. Am J Respir Crit Care Med Suppl 2004; 169:S812
27. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321:280-287
28. Soop A, Johansson C, Hjemdahl P, et al: Adenosine treatment attenuates cytokine in-terleukin-6 responses to endotoxin challenge in healthy volunteers. Shock 2003; 19: 503-507
29. Suffredini AF, Hochstein HD, McMahon FG: Dose-related inflammatory effects of intravenous endotoxin in humans: Evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis 1999; 179:1278-1282
30. El Kebir D, Taha R, Hubert B, et al: The anti-inflammatory effect of inhaled nitric oxide on pulmonary inflammation in a swine model. Can J Physiol Pharmacol 2005; 83: 252-258
31. Hataishi R, Rodrigues AC, Neilan TG, et al: Inhaled nitric oxide decreases infarction size and improves left ventricular function in a murine model of myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 291:H379-H384
32. Da J, Chen L, Hedenstierna G: Nitric oxide up-regulates the glucocorticoid receptor and blunts the inflammatory reaction in porcine endotoxin sepsis. Crit Care Med 2007; 35: 290-292
33. Fox-Robichaud A, Payne D, Hasan SU, et al: Inhaled NO as a viable antiadhesive therapy for ischemia/reperfusion injury of distal microvascular beds. J Clin Invest 1998; 101: 2497-2505
34. Adrie C, Bloch KD, Moreno PR, et al. Inhaled nitric oxide increases coronary artery patency after thrombolysis. Circulation 1996; 94:1919-1926
35. Klausen P, Niemann CU, Cowland JB, et al. On mouse and man: Neutrophil gelatinase associated lipocalin is not involved in apo-ptosis or acute response. Eur J Haematol 2005; 75:332-340
36. Copeland S, Warren HS, Lowry SF, et al: Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol 2005; 12:60-67
37. Maurenbrecher H, Lamy M, Deby-Dupont G, et al. An animal model of response and non-response to inhaled nitric oxide in endotox-in-induced lung injury. Chest 2001; 120: 573-581
38. Germann P, Braschi A, Della Rocca G, et al: Inhaled nitric oxide therapy in adults: European expert recommendations. Intensive Care Med 2005; 31:1029-1041
39. Soop A, Sollevi A, Weitzberg E, et al: Exhaled NO and plasma cGMP increase after endotoxin infusion in healthy volunteers. Eur Respir J 2003; 21:594-599
40. Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173:1008-1015